ライフサイエンスコーパス: WHO

1 WHO 2017;95:629).

2 WHO cutoffs for fast breathing and hypoxaemia overlap wi

3 WHO guidelines detected biologically implausible data in

4 WHO guidelines inform removal of population-based extrem

5 WHO guidelines recommend concurrent iron and antimalaria

6 WHO has launched a Global Initiative to scale up prevent

7 WHO is developing a global strategy towards eliminating

8 WHO recommends IPTp-SP in sub-Saharan Africa, but implem

9 WHO recommends the use of psychological interventions as

10 WHO requested updated modelling results for its 2019 Ant

11 WHO with additional support from MAP International, Amer

12 WHO, and UK Foreign Commonwealth and Development Office.

13 WHO, UNDP, UN Population Fund, UNICEF-WHO-World Bank Spe

14 WHO, UNDP, UN Population Fund, UNICEF-WHO-World Bank Spe

15 WHO, US Agency for International Development, and the Bi

16 WHO, US Agency for International Development, and US Pre

17 Fourteen percent (122/874) have >=1 WHO-defined mutation, of which 98% (120/122) are NNRTI m

18 untries, based on their implementation of 18 WHO-recommended NCD policies.

19 h advanced haematological malignancies (2008 WHO criteria) harbouring an IDH2 mutation.

20 three molecular groups according to the 2016 WHO classification system: (1) oligodendroglioma, IDH-mu

21 The 2016 WHO recommendation on the use of iNPWT for the preventio

22 We used the 2015 and 2017 WHO NCD progress monitor reports to calculate aggregate

23 , yet unsolved diagnostic issues in the 2017 WHO classification of myeloid neoplasms and the importan

24 th tests, assuming full adoption of the 2019 WHO guidelines for the use of these tests amongst those

25 T. solium transmission to support post-2020 WHO targets.

26 resectable colorectal liver metastases and a WHO performance status of 0-2 were randomly assigned (1:

27 -resistant Acinetobacter baumannii (CRAB), a WHO "critical priority pathogen" producing class D OXA-t

28 ho had not been previously treated and had a WHO performance status and American Society of Anesthesi

29 ventional therapy existed, and if they had a WHO performance status score of 0 or 1.

30 ore of at least 50, and a new diagnosis of a WHO (2002 criteria) intermediate (rarely metastasising)

31 We show that a WHO protein cleaves Torulaspora delbrueckii FBA1 efficie

32 The limit of detection was compared to a WHO-prequalified rapid diagnostic test (RDT).

33 or cytologically documented ES-SCLC, with a WHO performance status of 0 or 1.

34 ars of life lost can be avoided by achieving WHO's AQG and Chinese NAAQS in the study area, which cor

35 erence standards (IRRSs), calibrated against WHO SRIGs.

36 oefficient of variation), calibrated against WHO-1 and WHO-2 SRIGs, were: 1.8 IU/mL (18.7%) and 1.5 I

37 -highest implementation scores (86.1% of all WHO-recommended policies).

38 Unitage (IU/mL) was assigned using WHO-1 and WHO-2 SRIGs as calibrators.

39 of variation), calibrated against WHO-1 and WHO-2 SRIGs, were: 1.8 IU/mL (18.7%) and 1.5 IU/mL (17.8

40 ramme, year of ART initiation, CD4 count and WHO clinical stage at ART initiation, retention in HIV c

41 As incongruence between clinical course and WHO grade exists, reliable biomarkers have been sought.

42 prehensive search of the PubMed, Embase, and WHO Global Index Medicus electronic databases was perfor

43 prospectively tested by the Basel S-gene and WHO-based E-gene (Roche) assays in parallel using the Ba

44 ositis (Radiation Therapy Oncology Group and WHO scales) and 36-mo survival.

45 y rate was 2.7 times higher in the WHO-I and WHO-II TERT-alt patients compared with WHO-III TERTp-wt

46 kpoint of 0.12 mug/ml for the BMD method and WHO interim CCs of 1 mug/ml for MGIT and 0.25 mug/ml for

47 national Council of Nurses, Nursing Now, and WHO for nurses to move to higher levels of leadership, a

48 RT initiation, cumulative time with NVL, and WHO clinical stage and CD4 cell count at ART initiation,

49 umors version 1.1 for radiological scans and WHO criteria for medical photography.

50 tnership between the World Bank, UNICEF, and WHO.

51 Not having any WHO danger sign or consolidation on chest radiograph had

52 include children initiating age-appropriate WHO-recommended first-line regimens.

53 uidance document from UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropi

54 anemia (hemoglobin <=10 g/dL), and bleeding (WHO grade >=2).

55 TP groups are highly concordant with both WHO integrated histology and mutation classification as

56 ability Monitoring System assessment done by WHO and the Yemen Ministry of Public Health and Populati

57 D readiness indicators' from surveys done by WHO); health system finance (domestic government expendi

58 ange of the prevented fractions globally, by WHO region, and by World Bank income classification.

59 nt transmission-dynamic models identified by WHO according to predefined criteria, projected reductio

60 remains a high-threat pathogen identified by WHO as a priority pathogen because it causes severe dise

61 awi that would otherwise have been missed by WHO referral guidelines alone.

62 in 2015 using a risk factors-based model by WHO region.

63 broad stakeholder consultation organised by WHO and UNAIDS.

64 on designated as a public health priority by WHO.

65 7 to those listed in guidelines published by WHO and public health agencies in the UK and the USA.

66 rimary clinical trial registry recognised by WHO and the International Committee of Medical Journal E

67 nder half of the NCD policies recommended by WHO in 2017.

68 soproxil fumarate) previously recommended by WHO.

69 emoglobin saturation (SpO(2)) recommended by WHO.

70 istics of neurological disorders reported by WHO and other reputed organizations, nasal anatomy, mech

71 age III/IV) or colorectal (stage IV) cancer, WHO performance status 0-3, and at least 3 months life e

72 Enrolled CLHIV received standard of care WHO-recommended first-line ART.

73 World Health Organization functional class (WHO FC); and change in mean pulmonary arterial pressure

74 reas where air quality does not meet current WHO guidelines, combined with the knowledge that polluta

75 y gliomas with high agreement to the current WHO guidelines and may provide additional survival predi

76 The current WHO ILI case definition was highly specific but had low

77 etrovirals in 4 pharmacovigilance databases (WHO VigiAccess, 116 reactions; UK MHRA, 8 cases; EMA Eud

78 hing, and indicate that HO is a domesticated WHO-like element.

79 The DNA rearrangement steps during WHO element homing are very similar to those during mati

80 Most countries have endorsed WHO non-communicable disease (NCD) best buy policies, bu

81 ertable mortality from NCDs reduced in every WHO region and in most countries and territories between

82 ries worldwide and in many countries exceeds WHO-recommended rates.

83 ine, as required by pre-school children (FAO/WHO).

84 atory and experimental hut studies following WHO guidelines.

85 cytic intraepithelial neoplasia, and 81% for WHO classification system.

86 CNV may be a novel prognostic biomarker for WHO grade IV glioma patient outcomes.

87 ere diagnosed at a younger age, enriched for WHO grade I histology, infrequently progressed, and rare

88 We compared the two groups stratified for WHO grades as: incidence rates, survival probabilities a

89 ine Department of Health, Hanako Foundation, WHO, Swedish International Development Cooperation Agenc

90 l Research Council, Open Society Foundation, WHO, the Global Fund, UNAIDS, National Institute for Hea

91 i IMCI referral protocol, which differs from WHO protocol at the HC level and includes chest indrawin

92 In glioma WHO grade II, it is unclear whether the extent of MGMT p

93 lt occurred in 4.7%, 7.9% and 15.4% of WHO-I/WHO-II/WHO-III meningiomas, respectively.

94 integrated community case management (iCCM) WHO referral protocol and 3 (23%) and 4 (31%) of the 13

95 rred in 4.7%, 7.9% and 15.4% of WHO-I/WHO-II/WHO-III meningiomas, respectively.

96 rated management of childhood illness (IMCI) WHO protocol.

97 the recurrence rate was 4.8 times higher in WHO-I/-II TERT-alt patients compared with WHO-III TERTp-

98 nd acute myeloid leukaemia cases reported in WHO's pharmacovigilance database (VigiBase).

99 gainst MDR Gram-negative bacteria, including WHO priority pathogens.

100 lations were classified according to income, WHO region, gender, age, occupation and publication date

101 al obstruction syndrome; serious infections; WHO Bleeding Scale; transfusion requirements; and reacti

102 ta were prospectively captured by the ISARIC WHO CCP study.

103 ed, untreated mature T-cell or NK lymphomas (WHO 2001 or 2008 classifications) from 74 centres in 13

104 istan and determine what is required to meet WHO elimination targets for incidence.

105 ients in higher-resource settings would meet WHO eligibility criteria.

106 n who were 2 to 59 months of age and who met WHO criteria for nonsevere pneumonia with tachypnea were

107 Among those who met WHO pneumonia criteria, 8.6% (189/2199) experienced an a

108 nd adolescent health and nutrition (MNCAHN), WHO and UNICEF convened a group of experts, the Effectiv

109 stratified countries according to a modified WHO regional classification (Latin America, North Americ

110 y register data strengthening and a modified WHO Safe Childbirth Checklist; facilities in the interve

111 TERT-alt occurred in 4.7%, 7.9% and 15.4% of WHO-I/WHO-II/WHO-III meningiomas, respectively.

112 imed to explore the extracellular acidity of WHO grade II and III gliomas associated with 1p/19q co-d

113 We estimated the effects of WHO grade, age at diagnosis and sex as HRs.

114 Implementation of WHO-recommended NCD policies is increasing over time.

115 TERT-alt affected prognosis independent of WHO grades.

116 SpO2 < 90% predicted death independently of WHO danger signs compared with SpO2 >= 90%: HC Risk Rati

117 practices, starting from the integration of WHO treatment recommendations and the AWaRe classificati

118 ntigens and acceptable accuracy/linearity of WHO SRIGs using IRRSs as calibrators.

119 es in Ghana, Guinea, and Nigeria, as part of WHO's wider multicountry study on how women are treated

120 Use of WHO definitions for fast breathing could result in miscl

121 ches to CNS Tumour Taxonomy - Not Officially WHO (cIMPACT-NOW).

122 Among patients with HIV, use of at least one WHO Group A drug and specific use of moxifloxacin, levof

123 the safety of TwinrabTM in patients with one WHO approved vaccine regimen (Essen).

124 national burden, we used country-specific or WHO region-specific morbidity and mortality estimates an

125 ssue tumours, the World Health Organisation (WHO) classification categorises bone tumours based on th

126 The World Health Organisation (WHO) classification categorises musculoskeletal soft tis

127 Since 2015, the World Health Organisation (WHO) recommends immediate initiation of antiretroviral t

128 line (AQG) of the World Health Organization (WHO) (25 mug/m3).

129 2) thresholds and World Health Organization (WHO) and Malawi clinical guidelines for referral.

130 limit set by the World Health Organization (WHO) and the UN Food and Agriculture Organization (FAO)

131 World Health Organization (WHO) and United States of America (USA) categories of VI

132 gressively as the World Health Organization (WHO) annual air quality guideline (10 ug m(-3)) would re

133 below the current World Health Organization (WHO) annual standard (10 mug/m3).

134 ebruary 2020, the World Health Organization (WHO) assembled an international panel to develop animal

135 and femoral neck, World Health Organization (WHO) BMD categories at both sites, and plasma concentrat

136 The World Health Organization (WHO) called, in 2012, for a validated strategy towards T

137 ntity in the 2017 World Health Organization (WHO) classification of hematopoietic neoplasms.

138 ions with the new World Health Organization (WHO) classification.

139 The World Health Organization (WHO) currently recommends laboratory-confirmed diagnosis

140 The number of World Health Organization (WHO) danger signs demonstrated the highest discriminatio

141 study, 30+ years' World Health Organization (WHO) data have been analyzed, using a wide array of adva

142 1 March 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) a pand

143 n March 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19), which

144 the disease, the World Health Organization (WHO) declared the COVID-19 outbreak a pandemic-the first

145 (VA) based on the World Health Organization (WHO) definition of 'low vision' (<= 20/80) and US drivin

146 In 2016, the World Health Organization (WHO) developed the Eliminate YF Epidemics strategy aimin

147 identified by the World Health Organization (WHO) Evidence Review Group (ERG) on the Cardiotoxicity o

148 y 2019, untreated World Health Organization (WHO) grade II/III gliomas were analyzed by three neurora

149 World Health Organization (WHO) has issued guidelines for contact and droplet preca

150 The World Health Organization (WHO) has set elimination as a public health problem (EPH

151 The World Health Organization (WHO) international standard rabies immune globulins (SRI

152 In 2016, the World Health Organization (WHO) introduced global targets for the elimination of he

153 World Health Organization (WHO) member states have committed to global elimination,

154 R, defined by the World Health Organization (WHO) mutation list.

155 2199 (57.6%) met World Health Organization (WHO) pneumonia criteria.

156 The World Health Organization (WHO) recently concluded that road traffic noise increase

157 In 2018, the World Health Organization (WHO) recommended a modified 6-month treatment regimen fo

158 In 2016, the World Health Organization (WHO) recommended a shorter (9-12 month) multidrug-resist

159 The World Health Organization (WHO) recommends a standard assay that includes an RNA ex

160 The World Health Organization (WHO) recommends case definitions for influenza surveilla

161 The World Health Organization (WHO) recommends oral amoxicillin for patients who have p

162 The World Health Organization (WHO) recommends that communities should have a voice, be

163 The World Health Organization (WHO) recommends visual inspection of the cervix with ace

164 lated findings by World Health Organization (WHO) region, location, study period and design, composit

165 (UNDP)/World Bank/World Health Organization (WHO) Special Programme for Research and Training in Trop

166 rial outcomes and World Health Organization (WHO) testing guidance for the only licensed dengue vacci

167 has prompted the World Health Organization (WHO) to publish a vector alert calling for active mosqui

168 nes issued by the World Health Organization (WHO), US Center for Diseases Control (CDC) and European

169 We validated the World Health Organization (WHO)-recommended SARS-CoV-2 assay and analyzed the epide

170 evention (CDC) or World Health Organization (WHO).

171 according to the World Health Organization (WHO).

172 erm vision of the World Health Organization (WHO).

173 rent coverage and World Health Organization [WHO] Global Technical Strategy targets).

174 ilance databases (World Health Organization [WHO] VigiAccess; United Kingdom Medicines Health Regulat

175 e, hypoxic, or radiological pneumonia as per WHO definitions.

176 normal weight (BMI 18.5-24.9 kg/m(2), as per WHO's BMI categories), defined as the time from treatmen

177 O cost-effectiveness and strategic planning (WHO-CHOICE) methods to estimate pesticide-attributable s

178 Most participants (94%) had a positive WHO symptom screen for TB on enrollment, and 45% were di

179 ermitted level of lead in tap water (10 ppb; WHO, 2017), and fifteen times lower than the maximum BLL

180 predictive value of each symptom-predictor, WHO respiratory illness case definitions and a de novo d

181 The most recent WHO classification provides an updated classification sc

182 The most recent WHO classification provides an updated scheme that integ

183 artment of Reproductive Health and Research, WHO.

184 as a separate disease entity in the revised WHO classification has renewed efforts to improve the re

185 The World Health Organization's (WHO) hepatitis C virus (HCV) elimination target of an 80

186 f achieving the World Health Organization's (WHO) target of reducing gonorrhea incidence by 90% durin

187 and FibroScan (TREAT-B score and simplified WHO criteria) to select patients for antiviral therapy u

188 ial lesions and suggests that the simplified WHO classification scheme is appropriate for evaluation

189 ificantly higher than that of the simplified WHO criteria (p<0.001).

190 Compared to the simplified WHO criteria free from HBV DNA quantification, TREAT-B i

191 Since WHO declared the COVID-19 pandemic a Public Health Emerg

192 World Bank high-income countries and the six WHO regions (ie, Africa, the Americas, Southeast Asia, E

193 is study provides evidence needed to support WHO's final recommendation on use of PBO LLINs.

194 h benefits and be cost-effective, supporting WHO's strong recommendation for dolutegravir as a prefer

195 FeEC in bringing arsenic levels to less than WHO-MCL of 10 mug/L.

196 MVAs demonstrated that WHO subgroup was a significant predictor of PFS after ad

197 The WHO Access, Watch, and Reserve (AWaRe) framework was use

198 The WHO African region is expected to gain the greatest heal

199 The WHO Cervical Cancer Elimination Modelling Consortium (CC

200 The WHO Cervical Cancer Elimination Modelling Consortium (CC

201 The WHO Director-General has issued a call for action to eli

202 The WHO elimination strategy for hepatitis C virus advocates

203 The WHO influenza-like illness (ILI) definition was 16% sens

204 The WHO report focused on whole-day noise exposure, but new

205 most cost-effective strategy to achieve the WHO 90% hepatitis B birth dose coverage target in GBD re

206 el for other countries aiming to achieve the WHO HCV elimination targets.

207 up in screening and treatment to achieve the WHO hepatitis C elimination target of an 80% reduction i

208 R and 5th percentiles for SpO(2) against the WHO cutoffs, we found that the proportion of false posit

209 lanocytic intraepithelial neoplasia, and the WHO 4th edition classification of conjunctival melanocyt

210 ed LitCovid, medRxiv, Google Scholar and the WHO Covid-19 database for Covid-19 to 10 September 2020.

211 As the WHO declares this new contagion as a pandemic on the 11(

212 As the WHO treatment guidelines for schistosomiasis are current

213 alth Institute, and new partners such as the WHO Water Sanitation and Hygiene Group, UNDP, and UN-Hab

214 re PM2.5 levels were measured well below the WHO air quality standard.

215 the MARC zones and rates remained below the WHO recommended target of 100%.

216 c-resistant priority pathogens listed by the WHO, including Gram-negative bacteria in the critical pr

217 ity than the 80% coverage recommended by the WHO.

218 bility of new sequence data published by the WHO.

219 Despite the WHO's call for universal drug susceptibility testing for

220 nario of untreatable infection emerging, the WHO target is achievable if all MSM attending sexual hea

221 mellitus (T2DM) is a target priority for the WHO and the United Nations and is a key priority in the

222 Our findings provide support for the WHO recommendations for rapid ART initiation, and add to

223 gible patients successfully profiled for the WHO-defined molecular groups (n = 106/251), 26 (24%) wer

224 ountry-specific costs were obtained from the WHO-CHOICE database and denominated in 2017 internationa

225 rates peaking only at 35%, which is half the WHO-recommended coverage.

226 0 deaths worldwide, with the majority in the WHO Africa Region.

227 e mortality rate was 2.7 times higher in the WHO-I and WHO-II TERT-alt patients compared with WHO-III

228 These results informed the WHO 2019 dolutegravir paediatric dosing guidelines and h

229 c test in meningioma and integrated into the WHO classification.

230 Implementation of the WHO checklist resulted in an additional 5.9 complication

231 Implementation of the WHO checklist was a cost-effective strategy for improvin

232 alysis, for every 100 admissions, use of the WHO checklist was estimated to save $55,899.

233 new definition in the fourth edition of the WHO classification of the digestive tract tumors of 2010

234 component is based on the 2016 update of the WHO Classification of Tumors of the Central Nervous Syst

235 Our data confirm the clinical impact of the WHO classification that separates ISM from CM and from o

236 xt century, successful implementation of the WHO elimination strategy would reduce cervical cancer mo

237 imits, according to the fifth edition of the WHO guideline.

238 first to report the predictive value of the WHO-defined diagnostic classification in a set of unifor

239 the prognostic and predictive impact of the WHO-defined molecular subgroups and corresponding molecu

240 HO-FAST assay is an expanded redesign of the WHO-recommended reverse transcriptase PCRs (RT-PCRs).

241 experts in the field who were members of the WHO-UNAIDS Network for HIV Isolation and Characterisatio

242 s classified by the BMI-for-age based on the WHO growth charts.

243 -adrenoceptor acting drugs are listed on the WHO Model List of Essential Medicines.

244 tive pathogens, particularly bacteria on the WHO priority bacteria list.

245 2.5x binocular loupe and graded based on the WHO simplified grading system.

246 f value of -3 SDs from the median as per the WHO 2006 child growth standards.

247 ate trachoma as a public health problem, the WHO recommends the SAFE (Surgery, Antibiotics, Facial cl

248 Our results strongly support the WHO's call for surveillance and targeted vector control

249 from the Bayer pharmacovigilance system, the WHO VigiBase, and from the FDA Adverse Event Reporting S

250 will discuss the most recent updates to the WHO classification of bone tumours that are relevant to

251 will discuss the most recent updates to the WHO classification of STT that are relevant to radiologi

252 d and expressed as z scores according to the WHO Growth Standards.

253 on of cervical cancer mortality, we used the WHO mortality database.

254 with two indicators: preparedness, using the WHO International Health Regulations Monitoring and Eval

255 start, patient disease progression using the WHO scale up to 28 days, and time to complete resolution

256 We, the WHO HIVResNet working group, defined central areas of fu

257 HIV Cohort Study (SHCS) to test whether the WHO goals are achievable in this population.

258 SpO(2) was in reasonable agreement with the WHO definition of hypoxaemia in all regions except for P

259 With the WHO triple-intervention strategy, over the next 10 years

260 sensitivity of >90%, in accordance with the WHO's target-product profile for a triage test.

261 ma subgroups with 91.4% concordance with the WHO-defined mutation subtypes.

262 e well-characterized and registered with the WHO/IUIS while no catfish allergens have been described

263 ens, including TPI, were registered with the WHO/IUIS.

264 For premature deaths (age 30-69 years), the WHO triple-intervention strategy would result in rate re

265 These WHO elements home into the aldolase gene FBA1, replacing

266 When analysed separately for the three WHO subgroups, a similar association was only retained i

267 According to WHO criteria, Checklist scale-up is considered "very cos

268 uberculosis medications grouped according to WHO effectiveness categories.

269 pharyngeal swabs were collected according to WHO recommendations between 2015 and 2017 by using strat

270 of placebo (the test regimen), according to WHO weight bands (500 mg every 12 hours for a weight of

271 ith an experimental detection limit close to WHO guidelines.

272 ortality) were reported from 27 countries to WHO, the majority of which were reported by Saudi Arabia

273 Aggregated drug resistance data reported to WHO from either routine continuous surveillance or natio

274 Our data support the revision to WHO guidelines recommending the transition to dolutegrav

275 The switch to WHO-recommended dolutegravir (DTG)-based regimens could

276 t women and eliminate vertical transmission, WHO recommends offering oral pre-exposure prophylaxis (P

277 stitute for Health Research, Wellcome Trust, WHO, US Alzheimer's Association, and European Research C

278 WHO, UNDP, UN Population Fund, UNICEF-WHO-World Bank Special Program of Research, Development

279 WHO, UNDP, UN Population Fund, UNICEF-WHO-World Bank Special Program of Research, Development

280 ment, and the UNDP/UN Population Fund/UNICEF/WHO/World Bank Special Programme of Research, Developmen

281 nistry of Foreign Affairs, UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Developmen

282 UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Developmen

283 We used WHO cost-effectiveness and strategic planning (WHO-CHOIC

284 Using WHO categories, the crude incidence rate of any visual l

285 Unitage (IU/mL) was assigned using WHO-1 and WHO-2 SRIGs as calibrators.

286 Furthermore, using WHO's AQG and Chinese NAAQS as the references, we estima

287 16) among 3,393 households in Tanzania using WHO-recommended methods.

288 iac index was similar and most patients were WHO FC II and III after their respective interventions.

289 iority neglected zoonotic diseases for which WHO advocates control.

290 This trial in healthy adults with WHO category III exposure from suspected rabid animal al

291 icalTrials.gov, number NCT03353753, and with WHO International Clinical Trials Registry Platform, num

292 ons of differing severity: (1) children with WHO-defined severe malaria (n=1,544); (2) children admit

293 in WHO-I/-II TERT-alt patients compared with WHO-III TERTp-wt patients.

294 I and WHO-II TERT-alt patients compared with WHO-III TERTp-wt patients.

295 We compared these data with WHO RR and SpO(2) thresholds for tachypnoea and hypoxaem

296 he 'mouse-foot-pad propagation method', with WHO recommended concentration 0.01% mg/kg each DPC for 1

297 inferiority trial conducted in patients with WHO category III exposure with suspected rabid animal.

298 d with survival outcomes in 56 patients with WHO grade IV gliomas.

299 a practice-changing study for patients with WHO low-grade glioma (LGG, grade II), as it was the firs

300 t for age for children >=5 years fell within WHO recommendations.